SPOTLIGHT -
Slideshow
Author(s):
Some speculate the pharmaceutical industry has virtually abandoned new drug development in neuroscience with a few exceptions. However, it should be noted that progress has been made.
When the Fog Doesn’t Lift: Targeting Cognitive Dysfunction in Depression
Blue Light Blockers: A Behavior Therapy for Mania
Phase 2 Clinical Trial of AL001 for Major Depressive Disorder: Initiation Date Set for Late 2025
Blue Light, Depression, and Bipolar Disorder
The Week in Review: March 3-7
Ketamine, TMS Show Promise in Treatment-Resistant Depression in Older Adults